logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Small firms developing improved CAR T immunotherapy products.

We have a few small clinical stage firms in the Prohost Portfolio  that were established with the goal of designing safer and more effective versions of the very promising CAR T immuno-oncology products . We intend to revisit these firms...

Read More

December 28, 2018

0

Exelixis: A Big Yes from the FDA

Based on statistically significant results from the randomized phase 2 CABOSUN trial in patients with previously untreated renal cell carcinoma (RCC), the U.S. Food and Drug Administration (FDA) approved  Exelixis’ (EXEL) drug Cabometyx ®  (cabozantinib) for the expanded indication of patients with...

Read More

December 20, 2017

0

Juno and Spark: On the Road Towards Ambitious Goals

Juno Therapeutics (JUNO)  is one of the casualties that occurred during the 59 th  American Society of Hematology (ASH) Annual Meeting. The stock experienced undeserved selloff except for the fact that it had a deserved rally that we believe will remain...

Read More

December 12, 2017

0

Why We Decided Not To Abandon the Amgen and Illumina Band Wagons

Amgen Contrary to our expectations   Amgen’s ( AMGN ) shares declined more than 10% in 2019, instead of rallying . Part of the decline followed the threat of devastating the large drug creators and developers by lowering the high...

Read More

July 30, 2019

0

Bristol-Myers to acquire Celgene. Was this move really a surprise?

Bristol-Myers Squibb (BMY)   will acquire Celgene (CELG)  i n a cash and stock transaction with an equity value of approximately $74 billion . Under the terms of the agreement: Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00...

Read More

January 3, 2019

0

The FDA Accepted Seattle Genetics’ sBLA for Adcetris in Combination with Chemotherapy for Front-Line Treatment of Advanced Classical Hodgkin Lymphoma.

The Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (BLA) for  Seattle Genetics’ (SGEN)  product  Adcetris (brentuximab vedotin)  in combination with chemotherapy for the frontline treatment of patients with  advanced classical Hodgkin lymphoma.  The Agency granted Priority...

Read More

January 2, 2018

0

The Nektar Good News Cannot be Hidden Any Longer

Nektar Therapeutics We believe that Nektar Therapeutics ( NKTR )  is undervalued. We base this on the firm’s technological capability. Its current pipeline is filled with promising products. Today we learned that the U.S. FDA granted Nektar’s and Bristol-Myers Squibb’s ( BMY...

Read More

August 1, 2019

0

An Important Statement to Prohost Readers

Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and biopharmaceutical sectors. In this evaluation of hand-selected stocks, Prohost did not consider the negotiation between the U.S. and China a serious factor that could...

Read More

August 5, 2019

0

Why Loxo Oncology's and Sage Therapeutics' stocks staged a Rally today

Why Loxo Oncology and  Sage Therapeutics Have Occupied Today's Headline News LOXO Oncology Eli Lilly (LILY)  announced its intention to acquire Loxo Oncology (LOXO)   for around $8 billion in cash .  The offer translates to around $235 a share,...

Read More

January 7, 2019

0

What We Learned from Yesterday's and Today's Stocks' Moves

What Have We Learned from the Market's Recent Stock Moves? Well. Did we learn anything from what happened in the stock market and the reversal that started near the end of yesterday and occurred today? Listening to Larry Kudlow, the...

Read More

August 6, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 65
  • 66
  • 67
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy